Trials / Unknown
UnknownNCT02220244
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- MedDay Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MD1003 100mg capsule |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-12-01
- Completion
- 2018-01-01
- First posted
- 2014-08-19
- Last updated
- 2017-03-27
Locations
20 sites across 2 countries: France, United Kingdom
Source: ClinicalTrials.gov record NCT02220244. Inclusion in this directory is not an endorsement.